The Journal of Clinical Pharmacology

Cover image for The Journal of Clinical Pharmacology

August 2014

Volume 54, Issue 8

Pages i–vi, 841–957

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Special Section: Clopidogrel
    1. You have free access to this content
      Issue Information (pages i–vi)

      Article first published online: 5 JUL 2014 | DOI: 10.1002/jcph.358

  2. Special Section: Clopidogrel

    1. Top of page
    2. Issue Information
    3. Special Section: Clopidogrel
    1. Commentary

      You have free access to this content
    2. Continuing Education

      You have free access to this content
      Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants (pages 843–849)

      Efrén Martínez-Quintana, José M Medina-Gil, Fayna Rodríguez-González, Paloma Garay-Sánchez, José M Limiñana, Pedro Saavedra and Antonio Tugores

      Article first published online: 14 FEB 2014 | DOI: 10.1002/jcph.275

    3. Therapeutics

      You have free access to this content
      The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration (pages 850–857)

      Ho-Sook Kim, Doo-Yeoun Cho, Bo-Min Park, Soo-Kyoung Bae, Yune-Jung Yoon, Minkyung Oh, Jong-lyul Ghim, Eun-Young Kim, Dong-Hyun Kim and Jae-Gook Shin

      Article first published online: 26 NOV 2013 | DOI: 10.1002/jcph.225

    4. You have free access to this content
      Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine (pages 858–864)

      Takahiro Uotani, Mitsushige Sugimoto, Masafumi Nishino, Hitomi Ichikawa, Shu Sahara, Mihoko Yamade, Moriya Iwaizumi, Takanori Yamada, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura, Hiroshi Watanabe, Hiroaki Miyajima and Takahisa Furuta

      Article first published online: 21 MAR 2014 | DOI: 10.1002/jcph.284

    5. Editor's Choice

      You have free access to this content
      Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers (pages 865–873)

      Richard B. Horenstein, Rajnikanth Madabushi, Issam Zineh, Laura M. Yerges-Armstrong, Cody J. Peer, Robert N. Schuck, William Douglas Figg, Alan R. Shuldiner and Michael A. Pacanowski

      Article first published online: 7 APR 2014 | DOI: 10.1002/jcph.293

    6. Pharmacogenomics

      You have free access to this content
      The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases (pages 874–880)

      Marta Karaźniewicz-Łada, Dorota Danielak, Błażej Rubiś, Paweł Burchardt, Grzegorz Oszkinis and Franciszek Główka

      Article first published online: 6 MAY 2014 | DOI: 10.1002/jcph.323

    7. Commentary

      You have free access to this content
    8. You have free access to this content
      Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means (pages 884–888)

      Sudharshan Hariharan, Mary Ross Southworth and Rajanikanth Madabushi

      Article first published online: 5 JUL 2014 | DOI: 10.1002/jcph.337

    9. Adverse Drug Reactions

      The association of proton pump inhibitors and hypomagnesemia in the community setting (pages 889–895)

      Noa Markovits, Ronen Loebstein, Hillel Halkin, Martin Bialik, Janet Landes-Westerman, Joseph Lomnicky and Daniel Kurnik

      Article first published online: 6 MAY 2014 | DOI: 10.1002/jcph.316

    10. Pharmacogenomics

      Identification of VKORC1 genotype leading to resistance to tecarfarin (pages 896–900)

      Benjamin Matagrin, Adrien Montagut-Romans, Marlene Damin, Marc Lemaire, Florence Popowycz, Etienne Benoit and Virginie Lattard

      Article first published online: 5 JUL 2014 | DOI: 10.1002/jcph.332

    11. Special Populations

      An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis (pages 901–909)

      Jo-Anne S. Wilson, Kerry B. Goralski, Steven D. Soroka, Matthew Morrison, Paula Mossop, Lekha Sleno, Yan Wang and David R. Anderson

      Article first published online: 28 MAY 2014 | DOI: 10.1002/jcph.335

    12. Pharmacometrics

    13. You have full text access to this OnlineOpen article
      Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: Results from ROCKET AF (pages 917–927)

      I.G. Girgis, M.R. Patel, G.R. Peters, K.T. Moore, K.W. Mahaffey, C.C. Nessel, J.L. Halperin, R.M. Califf, K.A.A. Fox and R.C. Becker

      Article first published online: 26 MAR 2014 | DOI: 10.1002/jcph.288

    14. Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis (pages 937–948)

      Chihiro Hasegawa, Helen Kastrissios, Jonathan Monteleone, Tomoya Ohno, Takeo Umemura, Michiyo Ohyama, Shinichi Nagase, Maria Small, Steve Deacon, Mikio Ogawa and Ichiro Ieiri

      Article first published online: 28 FEB 2014 | DOI: 10.1002/jcph.279

    15. Pharmacokinetics

      Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers (pages 949–957)

      Thomas N. Kakuda, Magda Opsomer, Maarten Timmers, Koen Iterbeke, Tom Van De Casteele, Vera Hillewaert, Romana Petrovic and Richard M. W. Hoetelmans

      Article first published online: 26 MAR 2014 | DOI: 10.1002/jcph.290

SEARCH

SEARCH BY CITATION